JP2023068035A5 - - Google Patents

Download PDF

Info

Publication number
JP2023068035A5
JP2023068035A5 JP2023039774A JP2023039774A JP2023068035A5 JP 2023068035 A5 JP2023068035 A5 JP 2023068035A5 JP 2023039774 A JP2023039774 A JP 2023039774A JP 2023039774 A JP2023039774 A JP 2023039774A JP 2023068035 A5 JP2023068035 A5 JP 2023068035A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
strand
nucleic acid
composition according
ome
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2023039774A
Other languages
English (en)
Japanese (ja)
Other versions
JP7495544B2 (ja
JP2023068035A (ja
Filing date
Publication date
Priority claimed from EP17165007.0A external-priority patent/EP3385380A1/en
Priority claimed from PCT/EP2018/058764 external-priority patent/WO2018185240A1/en
Application filed filed Critical
Publication of JP2023068035A publication Critical patent/JP2023068035A/ja
Publication of JP2023068035A5 publication Critical patent/JP2023068035A5/ja
Application granted granted Critical
Publication of JP7495544B2 publication Critical patent/JP7495544B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2023039774A 2017-04-05 2023-03-14 産物及び組成物 Active JP7495544B2 (ja)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
EP17165007.0A EP3385380A1 (en) 2017-04-05 2017-04-05 Products and compositions
EP17165007.0 2017-04-05
EP17201405.2 2017-11-13
EP17201405 2017-11-13
PCT/EP2018/058764 WO2018185240A1 (en) 2017-04-05 2018-04-05 Products and compositions
JP2020504435A JP7247167B2 (ja) 2017-04-05 2018-04-05 産物及び組成物

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2020504435A Division JP7247167B2 (ja) 2017-04-05 2018-04-05 産物及び組成物

Publications (3)

Publication Number Publication Date
JP2023068035A JP2023068035A (ja) 2023-05-16
JP2023068035A5 true JP2023068035A5 (enExample) 2023-07-06
JP7495544B2 JP7495544B2 (ja) 2024-06-04

Family

ID=61899310

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2020504435A Active JP7247167B2 (ja) 2017-04-05 2018-04-05 産物及び組成物
JP2020554254A Active JP7419252B2 (ja) 2017-04-05 2019-04-05 アンチセンス鎖の5’末端でビニルホスホネートを有するsiRNA
JP2023039774A Active JP7495544B2 (ja) 2017-04-05 2023-03-14 産物及び組成物
JP2024001366A Pending JP2024036347A (ja) 2017-04-05 2024-01-09 アンチセンス鎖の5’末端でビニルホスホネートを有するsiRNA

Family Applications Before (2)

Application Number Title Priority Date Filing Date
JP2020504435A Active JP7247167B2 (ja) 2017-04-05 2018-04-05 産物及び組成物
JP2020554254A Active JP7419252B2 (ja) 2017-04-05 2019-04-05 アンチセンス鎖の5’末端でビニルホスホネートを有するsiRNA

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024001366A Pending JP2024036347A (ja) 2017-04-05 2024-01-09 アンチセンス鎖の5’末端でビニルホスホネートを有するsiRNA

Country Status (18)

Country Link
US (2) US11174483B2 (enExample)
EP (2) EP4219714A3 (enExample)
JP (4) JP7247167B2 (enExample)
KR (1) KR102589803B1 (enExample)
CN (2) CN110573619B (enExample)
AU (2) AU2018247924B2 (enExample)
CA (2) CA3057561C (enExample)
DK (1) DK3607068T3 (enExample)
ES (1) ES2936109T3 (enExample)
FI (1) FI3607068T3 (enExample)
HR (1) HRP20221547T1 (enExample)
HU (1) HUE061894T2 (enExample)
IL (2) IL269576B2 (enExample)
LT (1) LT3607068T (enExample)
PL (1) PL3607068T3 (enExample)
RS (1) RS63887B1 (enExample)
SI (1) SI3607068T1 (enExample)
WO (1) WO2018185240A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH12013501969B1 (en) 2011-03-29 2018-08-31 Alnylam Pharmaceuticals Inc Compositions and methods for inhibiting expression of tmprss6 gene
DK3607069T3 (da) * 2017-04-05 2022-11-21 Silence Therapeutics Gmbh Produkter og sammensætninger
IL269517B2 (en) 2017-04-05 2025-01-01 Silence Therapeutics Gmbh Nucleic acids for inhibiting expression of a target gene in a cell, conjugates thereof, compositions containing them, and medical uses thereof
EP3598995A1 (en) * 2018-07-26 2020-01-29 Silence Therapeutics GmbH Products and compositions
CN111973619B (zh) * 2019-05-23 2024-01-30 苏州瑞博生物技术股份有限公司 核酸、含有该核酸的药物组合物与siRNA缀合物及制备方法和用途
AU2022265493A1 (en) 2021-04-27 2023-09-21 Silence Therapeutics Gmbh Sirna targeting tmprss6 for the treatment of myeloproliferative disorders
TWI868755B (zh) 2022-06-24 2025-01-01 丹麥商諾佛 儂迪克股份有限公司 抑制跨膜絲胺酸蛋白酶6(tmprss6)表現的組成物及方法
WO2024060649A1 (zh) * 2022-09-29 2024-03-28 广州必贝特医药股份有限公司 用于抑制TMPRSS6基因表达的siRNA或其盐、药物及其应用
CN120981247A (zh) 2023-03-27 2025-11-18 赛伦斯治疗有限责任公司 用于干细胞移植的化合物和组合物
WO2025132845A1 (en) 2023-12-21 2025-06-26 Silence Therapeutics Gmbh Galnac phosphoramidites and their uses
WO2025163186A1 (en) * 2024-02-01 2025-08-07 Silence Therapeutics Gmbh Conjugated nucleic acids and nucleic acids comprising locked nucleosides and inverted nucleotides for inhibiting gene expression in a cell
WO2026003163A1 (en) 2024-06-26 2026-01-02 Silence Therapeutics Gmbh Sirna against tmprss6 for treating polycythemia vera

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL9201440A (nl) 1992-08-11 1994-03-01 Univ Leiden Triantennaire clusterglycosiden, hun bereiding en toepassing.
AU2003295600A1 (en) * 2002-11-14 2004-06-15 Dharmacon, Inc. Functional and hyperfunctional sirna
EP2601204B1 (en) * 2010-04-28 2016-09-07 Ionis Pharmaceuticals, Inc. Modified nucleosides and oligomeric compounds prepared therefrom
PH12013501969B1 (en) * 2011-03-29 2018-08-31 Alnylam Pharmaceuticals Inc Compositions and methods for inhibiting expression of tmprss6 gene
HRP20191883T1 (hr) * 2011-11-07 2019-12-27 Ionis Pharmaceuticals, Inc. Modulacija ekspresije tmprss6
KR102234623B1 (ko) * 2013-05-22 2021-04-02 알닐람 파마슈티칼스 인코포레이티드 Tmprss6 조성물 및 이의 사용 방법
IL316808A (en) * 2014-08-20 2025-01-01 Alnylam Pharmaceuticals Inc Modified double-stranded RNA materials and their uses
CN106795200B (zh) * 2014-10-10 2020-06-19 豪夫迈·罗氏有限公司 Galnac亚磷酰胺、其核酸缀合物及其用途
WO2016085852A1 (en) * 2014-11-24 2016-06-02 Alnylam Pharmaceuticals, Inc. Tmprss6 irna compositions and methods of use thereof
WO2016149020A1 (en) * 2015-03-17 2016-09-22 Arrowhead Research Corporation Rna interference agents
EP3228326A1 (en) 2016-04-05 2017-10-11 Silence Therapeutics GmbH Nucleic acid linked to a trivalent glycoconjugate
IL269517B2 (en) * 2017-04-05 2025-01-01 Silence Therapeutics Gmbh Nucleic acids for inhibiting expression of a target gene in a cell, conjugates thereof, compositions containing them, and medical uses thereof
DK3607069T3 (da) * 2017-04-05 2022-11-21 Silence Therapeutics Gmbh Produkter og sammensætninger

Similar Documents

Publication Publication Date Title
JP2023068035A5 (enExample)
JP2019214587A5 (enExample)
JP2022173554A5 (enExample)
JP2021533804A5 (enExample)
JP2021520207A5 (enExample)
JP2021502120A5 (enExample)
TWI880645B (zh) 抑制lpa之基因表現之組合物及方法
Shub et al. Structural conservation among three homologous introns of bacteriophage T4 and the group I introns of eukaryotes.
JP2020188756A5 (enExample)
JP2020530442A5 (enExample)
IL309503A (en) Innovative therapeutic delivery parts and their uses
IL274503B2 (en) Nucleic acids for inhibiting expression of lpa in a cell
JP2024079713A5 (enExample)
JP2021507709A5 (enExample)
JP2023504744A5 (enExample)
IL316808A (en) Modified double-stranded RNA materials and their uses
JP2020534268A (ja) アンジオポエチン様3(ANGPTL3)の発現を阻害するためのRNAi剤および組成物、ならびに使用方法
JP2018529732A5 (enExample)
JP2009514877A5 (enExample)
JP2021521796A5 (enExample)
JP2016520312A5 (enExample)
CN115516092A (zh) 血管生成素样3(ANGPTL3)的siRNA及其用途
WO2007056153B1 (en) Peptide-dicer substrate rna conjugates as delivery vehicles for sirna
JP2022503850A (ja) 産物及び組成物
JP2022503850A5 (enExample)